Cipla

1
Cipla
Cipla Limited
Type Public
Traded as
BSE:500087
[1]
NSE:CIPLA
[2]
BSE SENSEX Constituent
CNX Nifty Constituent
Industry Pharmaceuticals
Founded 1935
Founder(s) Dr. K. A. Hamied
Headquarters Mumbai, Maharashtra, India
Area served Worldwide
Key people Y. K. Hamied, Chairman
Subhanu Saxena (CEO)
Products Pharmaceuticals and diagnostics
Revenue 85.01 billion (US$1.4billion) (2012-13)
Net income 20.95 billion (US$350million) (2012-13)
Total assets 116.58 billion (US$1.9billion) (March 2013)
Total equity 90.19 billion (US$1.5billion) (March 2013)
Employees 27,562
Website
www.cipla.com
[3]
Cipla Limited is a pharmaceutical company based in Mumbai, India. Cipla makes drugs to treat cardiovascular
disease, arthritis, diabetes, weight control, depression and many other health conditions.
[4]
On 31 March 2013, its market capitalisation was INR 305 billion (US$ 5.6 billion), making it India's 41st largest
publicly traded company by market value.
History
It was founded by Dr. Khwaja Abdul Hamied as 'The Chemical, Industrial & Pharmaceutical Laboratories' in 1935
in Mumbai.
The name of the Company was changed to 'Cipla Limited' with effect from 20 July 1984, wherein the word Cipla
came from the first letters of each word in the old name 'The Chemical, Industrial & Pharmaceutical Laboratories'.
In the year 1985, US FDA approved the company's bulk drug manufacturing facilities.
In 1994, Cipla launched Deferiprone, the worlds first oral iron chelator.
In 2001, Cipla offered medicines (antiretrovirals) for HIV treatment at a fractional cost (less than $350 per year per
patient).
In 2012, the company slashed prices of three life-saving cancer drugs by 50-64%.
In 2013, it increased its stake in its South African joint venture CIPLA Medpro from 50% to 100% stake for INR 27
Cipla
2
billion to strengthen its position in the African continent. Cipla Medpro is the third largest South African
pharmaceutical company and it was founded in 1993.
Operations
Cipla has 34 manufacturing units in 8 locations across India and has presence in 170 countries. Exports accounted
for 52% of its revenue for FY 2012-13. Cipla cooperates with other enterprises in areas such as consulting,
commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.
Products and services
Cipla manufactures a range of pharmaceutical and personal care products. The company offers active pharmaceutical
ingredients (APIs); and formulations in therapeutic areas, such as allergy, analgesic, anti malarial, anti-infectives,
cardiology, dermatology and cosmeceuticals, diabetology, gastroenterology, HIV-AIDS, hormones and steroids, iron
chelators, musculoskeletal, neuropsychiatry, nutritional and ophthalmic products, oncology, respiratory, urology, and
womens health in various dosage forms. It also provides veterinary products for various animals, including
companion, equine, general care, live stock, and poultry. In addition, the company offers inhaled medication and
devices, such as dry powder inhalers, single-dose capsule and multi-dose dry powder inhalers, breath-actuated
metered dose inhalers, non-static spacers, baby and infant masks, and nasal sprays. Further, it provides consulting,
commissioning, plant engineering, and technical know-how transfer and support services.
Cipla has over 2000 products in 65 therapeutic categories available in over 40 dosage forms. Its key products include
the following drugs - Escitalopram (anti-depressant), Lamivudine, Fluticasone propionate.
HIV/AIDS medication
Cipla is the world's largest manufacturer of antiretroviral drugs (ARVs) to fight HIV/AIDS, as measured by units
produced and distributed (multinational brand-name drugs are much more expensive, so in money terms Cipla
medicines are probably somewhere down the list). Roughly 40 percent of HIV/AIDS patients undergoing
antiretroviral therapy worldwide take Cipla drugs.
Indian law from 1972 until 2005 allowed no (end-product) patents on drugs, and provided for compulsory licensing,
Cipla was able to manufacture medicines which enjoyed patent monopoly in certain other countries (particularly
those where large, multinational pharmaceutical companies are based).
Cipla also pioneered a three-in-one tablet called Triomune containing a fixed-dose combination (FDC) of three
ARVs (Lamivudine, stavudine and Nevirapine), something difficult elsewhere because the three patents were held
by different companies. Another popular fixed-dose combination is produced under the name Duovir-N. This
contains Lamivudine, Zidovudine and Nevirapine. Cipla manufactures generic versions of many of the most
commonly prescribed anti-retroviral medication in the market,
[5]
and is a highly capable manufacturer in its own
right. This innovation made ARVs far more accessible and easy-to-take for patients everywhere, but particularly in
poor- and middle-income countries, where the vast majority of people on anti-retroviral therapy (ART) now take
such combination pills.
Cipla was among the first companies to register AIDS drugs under the US relief program PEPFAR.
[6]
It has also
been a major supplier of ARVs to the Clinton Foundation's HIV/AIDS Initiative, which has negotiated low-cost drug
supplies for numerous developing countries.
Through its price offers to developing country governments and leading NGOs such as Doctors Without Borders
(MSF) and Oxfam, along with its keen participation in PEPFAR, the Global Fund, the Clinton Foundation's
HIV/AIDS Initiative and other major donor programs fighting HIV/AIDS in Africa and elsewhere in the
resource-poor world.
Cipla
3
Antiflu and Virenza
In December 2008, Cipla won a court case in India allowing it to manufacture a cheaper generic version of
oseltamivir, marketed by Hoffmann-La Roche (Roche) under the trade name Tamiflu, under the Cipla tradename
Antiflu. In May 2009, Cipla won approval from the World Health Organization certifying that its drug Antiflu was
as effective as Tamiflu, and Antiflu is included in the World Health Organization list of prequalified medicinal
products.
[7]
Cipla announced that Oseltamivir 75mg capsules marketed as `Antiflu` by the company has been included in the
World Health Organization (WHO) list of prequalified medicinal products (PMP).
Oseltamivir is indicated for use in the treatment of influenza A (H1N1) infection commonly known as swine flu.
Cipla also produces a generic version of zanamivir, marketed by Glaxo under the trade name Relenza, under the
Cipla tradename Virenza.
The New York Times reported that the government of Saudi Arabia purchased stockpiles of Antiflu in preparation
for Hajj in late 2009, fearing an outbreak of flu among Hajjis arriving from all parts of the world.
[8]
The firm announced the launch of the drug under the name "Antiflu" on 11 November 2009 to be sold as a category
X drug, strictly under prescription.
[9]
Cancer medications
In May 2012, Cipla made headlines by slashing prices on several cancer drugs. The Wall Street Journal quoted Cipla
chairperson Yusuf Hamied as saying: "We had taken the lead to provide affordable medicine for AIDS and I think
the time has now come -- 10 years later -- when we do a similar thing for cancer." The revised prices averaged
roughly 75% less than the previous ones, and Hamied announced plans to similarly reduce prices on the full range of
cancer drugs made by Cipla. The move was expected to prompt significant price drops from other producers,
providing access to medicine and saving many millions of cancer patients unnecessary suffering and/or death.
Other drugs
Asthalin - a CFC-free inhaler
Cipla also has a product range comprising antibiotics, anti-bacterials,
anti-asthmatics, anthelmintics, anti-ulcerants, oncology,
corticosteroids, nutritional supplements and cardiovascular drugs. The
company has at least nine different prescription drugs registered with
the US FDA.
[10]
Active in the anti-bacterial and anti-asthmatic
segments, Cipla was the first in Asia to launch a non-CFC metered
dose inhaler.
In a September 2011 article, The New York Times discussed Cipla's
efforts to radically lower costs of biotech drugs for cancer, diabetes
and other noncommunicable diseases, referencing the leading role the
company had played in getting low-cost AIDS drugs to the developing
world:
In retrospect, the battle 10 years ago over AIDS medicines was a small skirmish compared with the one likely
to erupt over cancer, diabetes and heart medicines. The AIDS drug market was never a major moneymaker for
global drug giants, while cancer and diabetes drugs are central to the companies very survival.
Cipla
4
Listings and shareholding
The equity shares of Cipla are listed on the Bombay Stock Exchange, where it is a constituent of the BSE SENSEX
index, and the National Stock Exchange of India, where it is a constituent of the S&P CNX Nifty. Its Global
Depository Receipts (GDRs) are listed on the Luxembourg Stock Exchange.
As on 30 September 2013, the promoter group, Dr. Y. K. Hamied and his family, held around 36.80% equity shares
in Cipla. Around 148,000 individual shareholders held approx. 18.67% of its shares. LIC is the largest non-promoter
shareholder with approx. 6.45% shareholding in the company by the end of September 2013.
Shareholders (as on 30-September-2013) Shareholding
Promoter Group 36.80%
Foreign Institutional Investors (FII) 23.78%
Individual shareholders 18.67%
Insurance companies 06.59%
Private Corporate Bodies 05.11%
Mutual Funds and UTI 04.11%
NRI/FCB/Others 03.90%
GDRs 01.04%
Total 100.0%
Employees
As on 31 March 2013, the company had 27,562 employees (out of which 2,012 were women (7.30%) and 3 were
employees with disabilities (0.01%)). During the FY 2012-13, the company incurred INR 10.36 billion on employee
benefit expenses.
Awards and recognitions
In April 2013, former US President Bill Clinton praised Cipla and other Indian generic drug companies for their
contribution in the fight against HIV/AIDS and noted that their cheap drugs saved millions of lives.
In 2012, Cipla received the Thomson Reuters India Innovation Award.
Cipla won Dun & Bradstreet American Express Corporate Awards for 2006.
In 2005, Forbes included Cipla in the 200 'Best under a billion' list of best small Asian companies.
In 1980, Cipla won Chemexcil Award for Excellence for exports.
In July 1939, Mahatama Gandhi (later conferred with the title "Father of the Nation" by Government of India)
visited Cipla.
Cipla
5
Initiatives
Palliative care:
Cipla established a hospice named 'Cipla Palliative Care and Training Centre' for terminally ill cancer patients in
Pune in 1997. The patient in this hospice get all medicines and services free of cost. The company, in its Annual
report for FY 2012-13, informed that it has cared for over 8,500 patients in last 16 years.
Criticism
Sale of emergency pregnancy termination pills over-the-counter:
In August 2007, Cipla launched pregnancy termination pill 'i-pill'. The morning-after pill was sold as the easiest way
to avoid unwanted pregnancies, but drew criticism as it was sold over-the-counter (hence not requiring a medical
prescription) and for the probable side effects. The drug contained twice the amount of main ingredient
levonorgestrel as compared to similar drugs such as Norlevo (Win Medicare) and Ecee2 from German Remedies.
One industry specialist noted that there was no evidence across the world of the drug being safe for females below
16 years of age. An industry insider, who also has products in oral contraception, said the amount of active
ingredient in the pill could cause problem in women with high blood pressure, heart disease. The same analyst noted
that the drug was not safe for people with problems such as liver disease, diabetes, migraines or asthma. Hence, if
the drug was distributed over the counter then there was no practical way to prevent people with aforementioned
issues or people below 16 years from buying the tablet.
Sale of generic drugs:
Generic pharmaceutical companies, like Cipla, are criticised by original drug manufacturers as they (generic pharma
companies) sell the products developed by others, without paying anything to the developers. The developers invest
a lot of money in research and development, clinical trials and marketing of the products. The medicine patent laws
in many developing countries, like India, allow generic pharma companies to produce branded medicines. On
average, the cost of a generic drug is 80 to 85 percent lower than the brand name product. This leads to criticism of
both the countries' patent laws and the generic companies as it denies the original manufactures of their share of
profits, a part of which they could have used for research and development of advanced medicines. The company in
its reply said that the population in the third world cannot afford the prices of medications that are prevailing in the
first world, and therefore medicines should be made available at affordable prices.
References
[1] http:/ / www. bseindia. com/ stock-share-price/ x/ y/ 500087/
[2] http:/ / www. nseindia. com/ marketinfo/ companyinfo/ companysearch. jsp?cons=CIPLA& section=7
[3] http:/ / www. cipla. com
[4] BusinessWeek (http:/ / investing. businessweek.com/ research/ stocks/ snapshot/ snapshot. asp?symbol=CIPL. BO)
[5] Generic HIV Medicine List (http:/ / www.aids-drugs-online. com/ antivirals. php)
[6] FDA (http:/ / www. fda.gov/ internationalprograms/ fdabeyondourbordersforeignoffices/ asiaandafrica/ ucm119231. htm)
[7] "Ciplas anti-flu drug gets nod" (http:/ / timesofindia. indiatimes. com/ Business/ India-Business/ Ciplas-anti-flu-drug-gets-nod/ articleshow/
4526891.cms), Times of India
[8] New York Times (http:/ / www. nytimes.com/ 2009/ 10/ 30/ world/ middleeast/ 30flu. html)
[9] Reuters (http:/ / in.reuters. com/ article/ companyNews/ idINBOM46139020091111?sp=true)
[10] US FDA (http:/ / www. accessdata.fda.gov/ )
Cipla
6
External links
Official website (http:/ / www. cipla. com)
Cipla - The Human Care Company (http:/ / www. lifescienceworld. in/ cipla_ final. html)
Facts about Generic Drugs (http:/ / www. fda. gov/ drugs/ resourcesforyou/ consumers/
buyingusingmedicinesafely/ understandinggenericdrugs/ ucm167991. htm) at U.S. Food and Drug Administration
Cipla (http:/ / timesofindia. indiatimes. com/ topic/ Cipla) at Times of India
Cipla (http:/ / www. bseindia. com/ stock-share-price/ cipla-ltd/ cipla/ 500087/ ) at Bombay Stock Exchange
Cipla (http:/ / www. nseindia. com/ live_market/ dynaContent/ live_watch/ get_quote/ GetQuote.
jsp?symbol=CIPLA) at National Stock Exchange of India
Business data
Cipla (https:/ / www. google. com/ finance?q=CIPL. NS) at Google Finance
Cipla (http:/ / finance. yahoo. com/ q?s=CIPLA. BO) at Yahoo! Finance
Cipla (http:/ / www. reuters. com/ finance/ stocks/ overview?symbol=CIPL. NS) at Reuters
Cipla (http:/ / www. hoovers. com/ company-information/ cs/ revenue-financial. Cipla_Limited.
091010a0bf5f6ba6. html) at Hoovers
Article Sources and Contributors
7
Article Sources and Contributors
Cipla Source: http://en.wikipedia.org/w/index.php?oldid=601455521 Contributors: 219.106 , Aaditya 7, Aecis, Ahivarn, Allens, Andrewman327, Anypodetos, Areyabhishek,
Armando-Martin, AxelBoldt, Baronnet, Bhadani, Biker Biker, Binary TSO, Brendonjohnliew, C6541, Catapult, Ceradon, Charles Matthews, Chillum, Cmdrjameson, Dcirovic, Deepakboraset,
Dl2000, Download, Dreadstar, EagerToddler39, Edgar181, Ehn, Epicgenius, Freakofnurture, Gaius Cornelius, Geetanjaliexcelsior, Gswarnkar, HelloAnnyong, Ilostmynuts, Infinitesimus, Itake,
Jamcib, JeffreyN, John Nevard, Johnpacklambert, Josve05a, Jovianeye, Khazar2, Kjc2002, Kkm010, Kufat, KuwarOnline, Larrygunnar1, Lbecque, Learnknowhelp, Liya sohil, MKar,
Magioladitis, Mainmahan, Mean as custard, Mr. 57, Nick Number, Ohconfucius, OscarK878, Ottawahitech, Pamri, Pradeepsomani, Ranbaxy1, Rd232 public, Rjs.swarnkar, Rjwilmsi,
RyanGerbil10, SFK2, Sfan00 IMG, Shanedidona, Skarebo, SlaveToTheWage, Sohailstyle, Sumit Kumar, Supremeknowledge, Swaraj.chhallani, Tharun S Yadla, The Sophisticated Boy,
Timothy.boyd, Tri400, Ufessler, Utcursch, Verne Equinox, Vigneshrk, Vimalkalyan, 140 anonymous edits
Image Sources, Licenses and Contributors
File:Cipla logo.svg Source: http://en.wikipedia.org/w/index.php?title=File:Cipla_logo.svg License: Public Domain Contributors: Cipla
File:Increase2.svg Source: http://en.wikipedia.org/w/index.php?title=File:Increase2.svg License: Public Domain Contributors: Sarang
File:Cipla inhaler.jpg Source: http://en.wikipedia.org/w/index.php?title=File:Cipla_inhaler.jpg License: Creative Commons Attribution-Sharealike 3.0 Contributors: Kristoferb (talk). Original
uploader was Kristoferb at en.wikipedia
License
Creative Commons Attribution-Share Alike 3.0
//creativecommons.org/licenses/by-sa/3.0/